BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Influenza
,
Embryo
,
Pharmacogenetics
,
Ciprofibrate
,
rs3825942
,
ZBTB7A
,
Angiogenesis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cell penetrating peptides
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
CENPE
CPA4
GDF15
CCL20
NECTIN4
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
FISCHER_DREAM_TARGETS
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP
DODD_NASOPHARYNGEAL_CARCINOMA_DN
LEE_BMP2_TARGETS_DN
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Acute monocytic leukemia MOLM-13 cells treated with the stapled peptide ALRN-6924
Ovarian carcinoma cells in response to a cell penetrating peptide ReACp53
Explore Curated Studies Results
Literature
Most Relevant Literature
Cell-penetrating peptides as antifungals towards Malassezia sympodialis.
Cell-penetrating peptides: classes, origin, and current landscape.
Therapeutic potential of cell-penetrating peptides.
Cell-penetrating peptides: 20 years later, where do we stand?
Modeling the endosomal escape of cell-penetrating peptides using a transmembrane pH gradient.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods …
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female …
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ